
    
      To evaluate the toxicities of PPX/RT To evaluate neuro-cognitive functional assessments of
      patients with GBM receiving PPX/RT To obtain preliminary data in a randomized phase II study
      whether PPX/RT improves overall survival as compared to temozolomide /RT for patients with
      GBM without MGMT methylation to facilitate planning a phase III study.
    
  